Humans make the best mAbs
Great therapeutic antibodies are rare. Finding the needle in the haystack is a daunting task as the frequency of the desired target approaches one in a million. CellSpot has solved the challenge of finding rare cells and antibodies by its unique combination of sensitive fluorescent nanoparticle multiplex detection, high speed microscopic imaging and proprietary software analysis /data reduction.
The result: rapid discovery of great antibodies.
Do you wish you could be one of those people who never seem to get sick?
The adaptive immune system has undergone evolutionary selection to protect and preserve good health. There are two key modes of protection: cell-mediated immunity against intracellular pathogens carried out by T lymphocytes; and humoral immunity against extracellular pathogens and toxins mediated by antibody-producing B lymphocytes. Enormous antibody diversity is supported by a germline repertoire of antibody V-genes shaped by direct interplay with humans and their complex environment. It is important to recognize that for every cell in the human body there are nearly 100 microorganisms coexisting in the body! Evidence of particular germline V-gene usage directed to vulnerable pathogen epitopes in multiple unrelated individuals has recently emerged. In vivo antigen-driven, iterative somatic hyper-mutation leads to exquisite levels of specificity and physiologically relevant affinity while preserving antibody structure, stability and safety. Screening human memory B cell antibody responses to specific target antigens, and selecting for optimal expression, function and binding kinetics harnesses the clinical potential of the human in vivo repertoire. Today, antibodies have become a well-established drug class with high rates of regulatory approval. Yet there is room for improvement in cure rate and safety. Trellis Bioscience has focused its discovery technology on selecting human antibodies directly from humans taking full advantage of in vivo optimization of the complex biology driving lead therapeutic antibody selection.